Grew Revenue 13% Sequentially to $32.2 Million Achieved Adjusted Gross Profit of $17.4 Million, Representing 54% Adjusted Gross Margin Conference Call to be Held May 15, 2024, at 6:00 p.m. ET COSTA MESA, Calif., May 15, 2024 /CNW/ - Gold Flora Corporation, ("Gold Flora" or the "Company") (Cboe Canada: GRAM) a leading vertically-integrated California cannabis company, announced its financial results for the three-month period ("Q1 2024"). All amounts are expressed in U.S. dollars. Q1 2024 Financial Highlights: Total revenue was $32.2 million, representing a 13% sequential grow
8-K - Gold Flora Corp. (0001876945) (Filer)
10-Q - Gold Flora Corp. (0001876945) (Filer)
RW - Gold Flora Corp. (0001876945) (Filer)
The Viridian Chart of the Week explores the relationship between financial strength and YTD stock performance. We broke the 30 MSO/SSOs that Viridian ranks each week into five different groups arranged with the strongest six companies on the left (Group 1) and the weakest six companies on the right (Group 5). Group 1: Green Thumb (OTC:GTBIF), Trulieve (OTC:TCNNF), Grown Rogue (OTC:GRUSF), Verano (OTC:VRNOF), Cresco (OTC:CRLBF) and Planet 13 (OTC:PLNH) Group 2: Curaleaf (OTC:CURLF), Cansortium (OTC:CNTMF) (proforma), C21 (OTC:CXXIF), MariMed (OTC:MRMD), Vext (OTC:VEXTF), and Ascend (OTC:AAWH) Group 3: AYR (OTC:AYRWF), TerrAscend (OTC:TSNDF), 1933 Industries (OTC:TGIFF), Gl
"For us, everything starts with cultivation," Laurie Holcomb founder and CEO of Gold Flora (OTC:GRAM) told the crowd gathered at the recent Benzinga cannabis event –Cannabis Market Spotlight on Monday in New Jersey. "We’ve got 107,000 square feet of canopy. It’s all indoor. So we’re one of the largest indoor cultivators in California.” This seed-to-sale publicly traded cannabis company is the third in terms of retail footprint and eighth in the California market in terms of shelf space. And that's not all, the company has about million dollars of accounts receivable (AR), which is a "phenomenal statistic, given the size of Gold Flora," according to Tom Zuber, a managing partner at Zuber L
As the premier gathering of top entrepreneurs and investors took place on Monday in New Jersey, we thought it would be a good time to scroll through the latest leadership changes in the cannabis and psychedelics industries. Cybin Inc. (NYSE:CYBN) (Cboe CA: CYBN) a clinical-stage biopharmaceutical company that develops new and innovative next-generation psychedelic-based treatment options, announced recently that Dr. Atul R. Mahableshwarkar M.D., DLFAPA, opted to join the company as senior vice president of clinical development. Dr. Mahableshwarkar agreed to lead the development of the CYB003 program, Cybin's proprietary deuterated psilocybin analog which has received U.S. Food and Drug
4 - Gold Flora Corp. (0001876945) (Issuer)
4/A - Gold Flora Corp. (0001876945) (Issuer)
4 - Gold Flora Corp. (0001876945) (Issuer)
Grew Revenue 13% Sequentially to $32.2 Million Achieved Adjusted Gross Profit of $17.4 Million, Representing 54% Adjusted Gross Margin Conference Call to be Held May 15, 2024, at 6:00 p.m. ET COSTA MESA, Calif., May 15, 2024 /CNW/ - Gold Flora Corporation, ("Gold Flora" or the "Company") (Cboe Canada: GRAM) a leading vertically-integrated California cannabis company, announced its financial results for the three-month period ("Q1 2024"). All amounts are expressed in U.S. dollars. Q1 2024 Financial Highlights: Total revenue was $32.2 million, representing a 13% sequential grow